Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study.
colorectal cancer
metastatic
multi-kinase inhibitor
prognosis
regorafenib
Journal
Clinical Medicine Insights. Oncology
ISSN: 1179-5549
Titre abrégé: Clin Med Insights Oncol
Pays: United States
ID NLM: 101525771
Informations de publication
Date de publication:
2019
2019
Historique:
received:
09
10
2018
accepted:
25
12
2018
entrez:
8
2
2019
pubmed:
8
2
2019
medline:
8
2
2019
Statut:
epublish
Résumé
Regorafenib is a multi-kinase inhibitor approved for treatment of refractory advanced colorectal cancer. It was found in the clinical trials to have a modest benefit and significant toxicity. Our aim was to assess the outcome in our local clinic practice. Records of patients with confirmed colorectal cancer treated with regorafenib were reviewed. Clinical, pathological, and molecular data were collected. Efficacy and factors of possible prognostic significance were analyzed. A total of 78 patients with metastatic colorectal cancer were treated with regorafenib from February 2014 to February 2016 in 4 different institutions (median age: 50.5 years; male: 40 [51.3%]; KRAS mutant: 41 [52%]; right colonic primary: 18 [23%]). A total of 52 patients (66.7%) had Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1, whereas in 25 patients (32.1%) it was >1. In total, 58 patients (74%) had dose reduction. No patient achieved objective response, 15 patients (19%) achieved stable disease, and 56 patients (72%) had progressive disease. With a median follow-up of 6.5 months, the median progression-free survival was 2.8 months (95% confidence interval [CI], 2.5-3.3) and overall survival was 8.0 months (95% CI, 6.2-9.7). Only performance status of ⩽1 had a statistically significant impact on progression-free survival and overall survival in both univariate and multivariate analyses. Regorafenib in our clinical practice has equal efficacy to reported data from pivotal registration trials. Our data suggest that performance status is the most important prognostic factor in patients treated with regorafenib, suggesting a careful selection of patients.
Sections du résumé
BACKGROUND
BACKGROUND
Regorafenib is a multi-kinase inhibitor approved for treatment of refractory advanced colorectal cancer. It was found in the clinical trials to have a modest benefit and significant toxicity. Our aim was to assess the outcome in our local clinic practice.
PATIENTS AND METHODS
METHODS
Records of patients with confirmed colorectal cancer treated with regorafenib were reviewed. Clinical, pathological, and molecular data were collected. Efficacy and factors of possible prognostic significance were analyzed.
RESULTS
RESULTS
A total of 78 patients with metastatic colorectal cancer were treated with regorafenib from February 2014 to February 2016 in 4 different institutions (median age: 50.5 years; male: 40 [51.3%]; KRAS mutant: 41 [52%]; right colonic primary: 18 [23%]). A total of 52 patients (66.7%) had Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1, whereas in 25 patients (32.1%) it was >1. In total, 58 patients (74%) had dose reduction. No patient achieved objective response, 15 patients (19%) achieved stable disease, and 56 patients (72%) had progressive disease. With a median follow-up of 6.5 months, the median progression-free survival was 2.8 months (95% confidence interval [CI], 2.5-3.3) and overall survival was 8.0 months (95% CI, 6.2-9.7). Only performance status of ⩽1 had a statistically significant impact on progression-free survival and overall survival in both univariate and multivariate analyses.
CONCLUSIONS
CONCLUSIONS
Regorafenib in our clinical practice has equal efficacy to reported data from pivotal registration trials. Our data suggest that performance status is the most important prognostic factor in patients treated with regorafenib, suggesting a careful selection of patients.
Identifiants
pubmed: 30728734
doi: 10.1177/1179554918825447
pii: 10.1177_1179554918825447
pmc: PMC6354297
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1179554918825447Déclaration de conflit d'intérêts
Declaration of conflicting interests:The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
N Engl J Med. 2004 Jun 3;350(23):2335-42
pubmed: 15175435
N Engl J Med. 2004 Jul 22;351(4):337-45
pubmed: 15269313
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Annu Rev Med. 2009;60:207-19
pubmed: 19630571
Int J Cancer. 2011 Jul 1;129(1):245-55
pubmed: 21170960
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Lancet. 2013 Jan 26;381(9863):303-12
pubmed: 23177514
Ann Oncol. 2014 Sep;25 Suppl 3:iii1-9
pubmed: 25190710
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Lancet Oncol. 2015 Jun;16(6):619-29
pubmed: 25981818
BMC Cancer. 2016 Jul 07;16:412
pubmed: 27389564
Asian Pac J Cancer Prev. ;18(9):2437-2444
pubmed: 28952273
Clin Colorectal Cancer. 2018 Dec;17(4):307-312
pubmed: 29548772
Med Oncol. 2018 Jun 23;35(8):114
pubmed: 29936654
Neoplasma. 2018;65(4):599-603
pubmed: 29940763